CD3 monitoring and thymoglobulin therapy in cardiac transplantation: Clinical outcomes and pharmacoeconomic implications

Walter E. Uber, L. A. Uber, A. B. VanBakel, A. J. Crumbley, N. L. Pereira, J. S. Ikonomidis, D. S. Feldman

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Introduction. CD3 monitoring of antithymocyte globulin therapy in renal transplantation has been shown to be more cost-effective than standard regimens. The objective of this study was to evaluate CD3 monitoring with Thymoglobulin in cardiac transplantation. Methods. Cardiac transplant patients who required antithymocyte globulin therapy were dose-adjusted to maintain absolute CD3 counts <25 cells/μL. Endomyocardial biopsies and hemodynamic parameters were used to assess efficacy. The incidences of hematological side effects, opportunistic infections, and malignancies were recorded; in addition we performed a cost comparison. Results. Eight patients were treated with Thymoglobulin using CD3 monitoring to adjust the dosing. All patients responded with few side effects. Compared to standard dosing, CD3 monitoring allowed a 60% reduction in the average total dose and a 58% reduction in cost per patient. Conclusion. CD3 monitoring of Thymoglobulin therapy in cardiac transplant patients results in lower doses and reduced costs with equivalent efficacy and a low incidence of complications.

Original languageEnglish (US)
Pages (from-to)3245-3249
Number of pages5
JournalTransplantation proceedings
Volume36
Issue number10
DOIs
StatePublished - Jan 1 2004

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Fingerprint Dive into the research topics of 'CD3 monitoring and thymoglobulin therapy in cardiac transplantation: Clinical outcomes and pharmacoeconomic implications'. Together they form a unique fingerprint.

  • Cite this